Wall Street analysts expect Rubius Therapeutics Inc (NASDAQ:RUBY) to report earnings per share (EPS) of ($0.40) for the current quarter, Zacks reports. Zero analysts have issued estimates for Rubius Therapeutics’ earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.31). The business is scheduled to issue its next earnings results on Tuesday, February 12th.
According to Zacks, analysts expect that Rubius Therapeutics will report full-year earnings of ($1.74) per share for the current fiscal year, with EPS estimates ranging from ($2.80) to ($1.05). For the next financial year, analysts forecast that the company will post earnings of ($1.56) per share, with EPS estimates ranging from ($2.20) to ($0.93). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Rubius Therapeutics.
Rubius Therapeutics (NASDAQ:RUBY) last issued its earnings results on Tuesday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06).
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American International Group Inc. bought a new stake in shares of Rubius Therapeutics in the 3rd quarter valued at about $194,000. Rhumbline Advisers bought a new stake in shares of Rubius Therapeutics in the 3rd quarter valued at about $207,000. Zimmer Partners LP bought a new stake in shares of Rubius Therapeutics in the 3rd quarter valued at about $360,000. TIAA CREF Investment Management LLC bought a new stake in shares of Rubius Therapeutics in the 3rd quarter valued at about $392,000. Finally, MetLife Investment Advisors LLC bought a new stake in shares of Rubius Therapeutics in the 3rd quarter valued at about $405,000. Hedge funds and other institutional investors own 81.17% of the company’s stock.
RUBY traded down $0.53 on Friday, reaching $20.70. The stock had a trading volume of 705 shares, compared to its average volume of 88,329. Rubius Therapeutics has a fifty-two week low of $14.50 and a fifty-two week high of $33.01. The company has a quick ratio of 25.78, a current ratio of 25.78 and a debt-to-equity ratio of 0.06.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Featured Article: Understanding Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.